|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/48 | |
| A61P 7/04 |
| (11) | Patento numeris | 1761274 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 05756838.8 |
| Europos patento paraiškos padavimo data | 2005-06-21 | |
| (97) | Europos patento paraiškos paskelbimo data | 2007-03-14 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2009-09-02 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2005/052890 |
| Data | 2005-06-21 |
| (87) | Numeris | WO 2005/123118 |
| Data | 2005-12-29 |
| (30) | Numeris | Data | Šalis |
| 200400972 | 2004-06-21 | DK | |
| 200400981 | 2004-06-23 | DK |
| (72) |
BRUN, Nikolai Constantin, DK
ERHARDTSEN, Elisabeth, DK
SKOLNICK, Brett E., US
|
| (73) |
Novo Nordisk Health Care AG,
Andreasstrasse 15, 8050 Zürich,
CH
|
| (54) | FACTOR VIIA OR FACTOR VIIA EQUIVALENTS FOR PREVENTING OR ATTENTUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) |
| FACTOR VIIA OR FACTOR VIIA EQUIVALENTS FOR PREVENTING OR ATTENTUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) |